Filing Flows › Health Care › Medinotec (MDNC)
Medinotec (MDNC) earnings and revenue breakdown
Latest: Q2 FY27 · 10-Q filed Oct 8, 2026 · Medinotec (MDNC) Q2 FY27 earnings results →
Q2 FY27 Revenue down 1% year over year to $3.2M · 1¢ of every $1 of revenue kept as net profit · operating margin 6.3%
Medinotec made $3.2M in Q2 FY27 (-1% Y/Y): Outside the United States $3.0M, Inside U S A Internally Designed Manufactured Sales $200K. Operating margin 6.3%, net earnings $41K. See where every dollar goes — costs, profit and cash — as a Sankey from the 10-Q filed Oct 8, 2026.
Drawing the Sankey…
Open the interactive Sankey → click any line for what the company wrote about it, compare Y/Y and Q/Q, export as PNG or PDF
What changed this quarter
Revenue was $3.2M in Q2 FY27, down 1% year over year and up 21% from the previous quarter. Outside U S A Distribution Agreement Sales was the largest line at 86% of revenue. Outside U S A Internally Designed Manufactured Sales lost $66K year over year (down 21%), 185% of the total change.
Gross margin was 48.7%, down 12.5 points from Q2 FY26. Operating profit was $203K, a 6.3% margin (down 10.0 points year over year). Operating expenses fell 7% while revenue fell 1%. The fastest-growing cost line was Other operating costs (+191%). Net earnings were $41K, down 88% year over year. The effective tax rate was 77.3%.
Operating cash flow was $108K (down 91% year over year), 263% of net earnings. Non-cash charges added back $22K of depreciation and amortization. Working capital and other items added $45K. Capital expenditures of $47K left free cash flow of $61K.
Quarterly history
| Quarter | Form | Filed | Revenue | Y/Y | Op. margin | Net earnings | Op. cash flow |
|---|---|---|---|---|---|---|---|
| Q2 FY27 | 10-Q | Oct 8, 2026 | $3.2M | -1% | 6.3% | $41K | $108K |
| Q1 FY27 | 10-Q | Jul 9, 2026 | $2.7M | +24% | 6.8% | $222K | −$176K |
| Q4 FY26 | 10-K | May 28, 2026 | $1.8M | -48% | -14.5% | −$69K | −$121K |
| Q3 FY26 | 10-Q | Jan 9, 2026 | $2.5M | -1% | 21.8% | $403K | $563K |
| Q2 FY26 | 10-Q | Oct 8, 2025 | $3.2M | +79% | 16.3% | $347K | $1.2M |
| Q1 FY26 | 10-Q | Jul 16, 2025 | $2.1M | +70% | 13.0% | $114K | −$759K |
| Q4 FY25 | 10-K | May 29, 2025 | $3.5M | +57% | 55.6% | $1.5M | $99K |
Charts
Interactive views
The same charts as the app — open one to draw it.
💵Where each $1 goesinteractive
Loading the interactive chart…
🌏Named in Asian annual reportsinteractive
Loading the interactive chart…
🔄Rotation against the market and its industry (RRG)interactive
Loading the interactive chart…
🔍Earnings qualityinteractive
Loading the interactive chart…
⚖️Fair value by methodinteractive
Loading the interactive chart…
🔭Outlook & guidanceinteractive
Loading the interactive chart…
📈Investments: gains and what it boughtinteractive
Loading the interactive chart…
🏭Its industry’s money flow (input-output)interactive
Loading the interactive chart…
About Medinotec
Medinotec Inc. is a U.S.-based company incorporated in Nevada. The Company’s primary operations are conducted through its wholly owned subsidiaries, Medinotec Capital (Pty) Ltd and DISA Medinotec (Pty) Ltd (“DISA Medinotec”), both of which are incorporated in South Africa. Medinotec Capital (Pty) Ltd serves as an investment holding company, whilst DISA Medinotec is engaged in the design, manufacture and distribution of medical devices. The Company’s operations include the development, manufacture and commercialization of medical devices, as well as the establishment and management of related distribution channels. The Company currently has operations in South Africa and the United States, including activity conducted from our short-term office and storage space in Melville, New York.
In its own words, from its 10-Q, filed Oct 8, 2026.
Medinotec against its Surgical & Medical Instruments & Apparatus peers
The largest companies of the same SEC industry, each at its latest quarter. Revenue growth: -1% against the peers' median +5%. Operating margin: 6.3% against the peers' median 13.3%.
| Company | Quarter | Revenue | Y/Y | Op. margin |
|---|---|---|---|---|
| MDNC Medinotec | Q2 FY27 | $3.2M | -1% | 6.3% |
| MDLN Medline | Q3 2026 | $7.9B | +10% | 6.4% |
| MMM 3M | Q3 2026 | $6.6B | +1% | 23.7% |
| SYK Stryker | Q3 2026 | $6.5B | +8% | 15.9% |
| BSX Boston Scientific | Q3 2026 | $5.1B | +1% | 16.1% |
| BDX Becton Dickinson | Q3 FY26 | $5.0B | +5% | 13.3% |
| BAX Baxter International | Q3 2026 | $3.0B | +5% | 7.6% |
| SOLV Solventum | Q3 2026 | $1.9B | -7% | 3.5% |
| RMD ResMed | Q1 FY27 | $1.4B | +6% | 32.0% |
Source: Medinotec 10-Q on SEC EDGAR · CIK 1931055 · Surgical & Medical Instruments & Apparatus
More on MDNC
History
Every quarter: Q2 FY27 results · Q1 FY27 results · Q4 FY26 results · Q3 FY26 results · Q2 FY26 results · Q1 FY26 results · Q4 FY25 results